Cell and Gene Therapy
A section of Cells (ISSN 2073-4409).
Section Information
Cell gene therapy involves two aspects: cell therapy and gene therapy. Cell therapy is a method that uses the patient's own or donor cells to stimulate an immune response or cell regeneration to kill pathogens and tumor cells. It includes immune cell therapy, stem cell therapy, and somatic cell therapy. Gene therapy is an approach based on treating disease via modifying (through introduction, removal, and change) the patient's genes. In the past few decades, the research on cell and gene therapy has developed rapidly and this is now emerging as an alternative therapy for many diseases.
The Section “Cell and Gene Therapy” aims to encourage research that focuses on the research progress of cell gene therapy in tumors, genetic diseases, cardiovascular diseases, autoimmune diseases, and some rare diseases. We welcome original research, review articles, communications, and technical notes on topics including, but not limited to, the following:
- Immunotherapy;
- Adoptive Cell Therapy;
- Stem Cell Therapy;
- CAR-T Cell Therapy
- Cell Culture;
- Tissue Engineering and Regenerative Medicine;
- Epigenetics and Stem Cell Biology;
- Genomic Medicine;
- Bioengineering and Therapeutic Sciences;
- Transgenic Animal Models;
- Immunogenetics;
- Transplantation and Immunology;
- Biomarkers;
- Viral Vector;
- Bacterial Vector;
- Genome Editing;
- Plasmid DNA;
- Oncolytic Virus;
- RNA Therapeutics;
- Vaccine.
Editorial Board
Special Issues
Following special issues within this section are currently open for submissions:
- Advances in Muscle Stem Cells and Development (Deadline: 15 December 2024)
- The Role of MDM2 in Tumor Biology and Cancer Therapy (Deadline: 31 December 2024)
- Novel Therapeutic Targets and Approaches, Genetic Markers and Signaling Pathways in Neoplasms (Deadline: 25 March 2025)
- CRISPR-Based Genome Editing Approaches in Cancer Therapy (Deadline: 31 March 2025)
Topical Collections
Following topical collections within this section are currently open for submissions: